Diagnostic significance of anti-annexin-A5 antibody determination

• Authors: Marta Baleva , Maria Hristova , Krasimir Nikolov
• Languages of publication: EN

Abstracts

EN

Anti-annexin A5 antibodies are directed against annexin A5 - a phospholipid-binding protein that belongs to the ubiquitous annexin family. These antibodies were first discovered in 1994 by Matsuda et al. in women with recurrent fetal loss or preeclampsia and in patients with systemic lupus erythematosus and positive lupus anticoagulant and/or anticardiolipin antibodies. Since then anti-annexin A5 antibodies have been the focus of research. In addition to their well known prothrombotic and procoagulant activities the authors discuss the involvement of these antibodies in the pathogenesis of antiphospholipid syndrome, recurrent pregnancy loss, systemic lupus erythematosus and other immune and non-immune disorders. Controversial reports are presented and a possible interpretation of the results is given. The authors suggest the significance of anti-annexin A5 antibodies as an additional diagnostic marker and discuss the necessity of more extensive research on their clinical significance.

Keywords

EN

Anti-annexin A5 antibodies; Antiphospholipid syndrome; Pregnancy loss; Systemic lupus erythematosus

• Publisher: De Gruyter Open
• Journal: Open Medicine
• Year: 2010
• Volume: 5
• Issue: 1
• Pages: 6-11

Dates

published

1 - 2 - 2010

online

29 - 1 - 2010

Contributors

author

Marta Baleva

• Laboratory of Clinical Immunology, University Hospital Alexnadrovska, Medical University, 1431, Sofia, Bulgaria

author

Maria Hristova

• Laboratory of Clinical Immunology, University Hospital Alexnadrovska, Medical University, 1431, Sofia, Bulgaria

author

Krasimir Nikolov

• Department of Dermatovenereology, St. Anna Hospital, Medical University, 9000, Varna, Bulgaria

References

• [1] Matsuda J., Gotoh M., Saitoh N., Gohchi K., Tsukamoto M., Yamamoto T., Anti-annexin V antibody in the sera of patients with habitual fetal loss or preeclampsia, Thromb. Res., 1994, 75,1, 105–106 http://dx.doi.org/10.1016/0049-3848(94)90145-7[Crossref]
• [2] Matsuda J., Saitoh N., Gohchi K., Tsukamoto M., Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody, Am. J. Hematol., 1994, 47,1, 56–58 http://dx.doi.org/10.1002/ajh.2830470112[Crossref]
• [3] Pengo V., Thiagarajan P., Shapiro S.S., Heine M.J., Immunologic specificity and mechanism of action of IgG lupus anticoagulant, Blood, 1987, 70, 69–76
• [4] Harris E.N., Antiphospholipid antibodies, Br. J. Haematol, 1990, 74, 1–9 http://dx.doi.org/10.1111/j.1365-2141.1990.tb02530.x[Crossref]
• [5] McNeil H.P., Simpson R.J., Chesterman C.N., Krilis S.A., Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta-2-glycoprotein I (apolipoprotein H), Proc. Natl. Acad. Sci. U.S.A., 1990, 87, 4120–4124 http://dx.doi.org/10.1073/pnas.87.11.4120
• [6] Galli M., Comfurius P., Maassen C., Hemker H.C., de Baets M.H., van Breda-Vriesman P.J. et al., Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma cofactor, Lancet, 1990, 335, 1554–1557 http://dx.doi.org/10.1016/0140-6736(90)91374-J[Crossref]
• [7] Matsuura E., Igarashi Y., Fujimoto M., Ichikawa K., Koike T., Anticardiolipin cofactor (s) and differential diagnosis of autoimmune disease, Lancet, 1990, 336, 177–178 http://dx.doi.org/10.1016/0140-6736(90)91697-9[Crossref]
• [8] Vermylen J., Arnout J., Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes, J. Lab. Clin. Med., 1992, 120, 10–12
• [9] Nakamura N., Kuragaki C., Shidara Y., Yamaji K., Wada Y., Antibody to annexin V has anti-phospholipid and lupus anticoagulant properties, Am. J. Hematol., 1995, 49, 347–348 http://dx.doi.org/10.1002/ajh.2830490414[Crossref]
• [10] Kuragaki C., Kidoguchi K., Nakamura N., Wada Y., Anti-annexin V antibodies in plasma and serum from patients with lupus anticoagulant, Am. J. Hematol., 1995, 50, 68 http://dx.doi.org/10.1002/ajh.2830500122[Crossref]
• [11] Rand J.H., Wu X.X., Andree H.A., Lockwood C.J., Guller S., Scher J., Harpel P.C., Pregnancy loss in the antiphospholipid antibody syndrome - a possible thrombogenic mechanism, N. Engl. J. Med., 1997, 337, 154–160 http://dx.doi.org/10.1056/NEJM199707173370303[Crossref]
• [12] Rote N.S., Antiphospholipid antibodies, annexin V and pregnancy loss, (Letter) N. Engl. J. Med., 1997, 337, 1630–1631 http://dx.doi.org/10.1056/NEJM199711273372214[Crossref]
• [13] Cheng H.M. Antiphospholipid antibodies, annexin V and pregnancy loss, (Letter) N. Engl. J. Med., 1997, 337, 1630–1631 http://dx.doi.org/10.1056/NEJM199711273372214[Crossref]
• [14] Rand J.H., Lockwood C.J. Antiphospholipid antibodies, annexin V and pregnancy loss, (Letter) N. Engl. J. Med., 1997, 337, 1630–1631 http://dx.doi.org/10.1056/NEJM199711273372214[Crossref]
• [15] Di Simone N., Castellani R., Caliandro D., Caruso A., Monoclonal anti-annexin V antibody inhibits trophoblast gonadotropin secretion and induces syncytiotrophoblast apoptosis, Biology of reproduction, 65, 2001, 1766–1770 http://dx.doi.org/10.1095/biolreprod65.6.1766[Crossref]
• [16] Rand J.H., Wu X.X., Lapinski R., van Heerde W.L., Reutelingsperger C.P., Chen P.P. et al., Detection of antibody mediated reduction of annexin V anticoagulant activity in plasmas of patients with antiphospholipid syndrome, Blood, 2004, 104,9, 2783–2790 http://dx.doi.org/10.1182/blood-2004-01-0203[Crossref]
• [17] Hanly J.G., Smith S.A., Anti-beta2-glycoprotein I (GPI) antibodies, annexin V binding and the antiphospholipid syndrome, Clin. Exp. Immunol., 2000,120,3, 537–543 http://dx.doi.org/10.1046/j.1365-2249.2000.01248.x
• [18] de Laat B., Wu X.X., van Lummel M., Derksen R.H., de Groot P.G., Rand J.H., Correlation between antiphospholipid antibodies that recognize domain I of beta2-glycoprotein I and a reduction in the anticoagulant activity of annexin, Blood, 2007,109,4,1490–1494 http://dx.doi.org/10.1182/blood-2006-07-030148[WoS][Crossref]
• [19] Gris J.C., Quéré I., Sanmarco M., Boutiere B., Mercier E., Amiral J., et al., Antiphospholipid and antiprotein syndromes in non-thrombotic, nonautoimmune women with unexplained recurrent early foetal loss, The Nimes Obstetricians and Haematologists Study - NOHA., Thromb. Haemost, 2000, 84, 228–236
• [20] Schild H., Rötzschke O., Kalbacher H., Rammensee H.G., Limit of T cell tolerance to self proteins by peptide presentation, Science, 1990, 247, 1587–1589 http://dx.doi.org/10.1126/science.2321019[Crossref]
• [21] Wang X., Campos B., Kaetzel M.A., Dedman J.R. Annexin V is critical in the maintenance of murine placental integrity, Am. J. Obstet. Gynecol., 1999, 180, 1008–1016 http://dx.doi.org/10.1016/S0002-9378(99)70674-5[Crossref]
• [22] Ogawa H., Zhao D., Dlott J.S., Cameron G.S., Yamazaki M., Hata T., et al., Elevated anti-annexin V antibody levels in antiphospholipid syndrome and their involvement in antiphospholipid antibody specificities, Am. J. Clin. Pathol., 2000, 114, 619–628 http://dx.doi.org/10.1309/298H-NLBU-E47G-8PYL[Crossref]
• [23] Siaka C., Lambert M., Caron C., Amiral J., Hachulla E., Hatron P.Y., et al., Low prevalence of anti-annexin V antibodies in antiphospholipid syndrome with fetal loss, Rev. Med. Intern., 1999, 20,9, 762–765 http://dx.doi.org/10.1016/S0248-8663(00)88682-8[Crossref]
• [24] Arai T., Matsubayashi H., Sugi T., Kondo A., Shida M., Suzuki T., et al., Anti-annexin A5 antibodies in reproductive failures in relation to antiphospholipid antibodies and phosphatidylserine, Am. J. Reprod. Immunol., 2003, 50,3, 202–208 http://dx.doi.org/10.1034/j.1600-0897.2003.00069.x[Crossref]
• [25] Arnold J., Holmes Z., Pickering W., Farmer C., Regan L., Cohen H., Anti-beta 2 glycoprotein 1 and anti-annexin V antibodies in women with recurrent miscarriage, Br. J. Haematol., 2001, 113, 911–914 http://dx.doi.org/10.1046/j.1365-2141.2001.02812.x
• [26] Ulcová-Gallová Z., Mukengnábl P., Hadravská S., Bibková K., Slechtová J., Kyselová V. et al., Placenta and annexin V receptors, antibodies against annexin V and against other phospholipids in patients with recurrent pregnancy loss, Ceska Gynekol., 2006, 71, 469–473
• [27] Bizzaro N., Tonutti E., Villalta D., Tampoia M., Tozzoli R., Prevalence and clinical correlation of anti-phospholipid-binding protein antibodies in anticardiolipin-negative patients with systemic lupus erythematosus and women with unexplained recurrent miscarriages, Arch. Pathol. Lab. Med., 2005, 129, 61–68
• [28] Zammiti W., Mtiraoui N., Kallel C., Mercier E., Almawi W.Y., Mahjoub T., A case-control study on the association of idiopathic recurrent pregnancy loss with autoantibodies against beta2-glycoprotein I and annexin V, Reproduction 2006, 131, 817–822 http://dx.doi.org/10.1530/rep.1.01060[Crossref]
• [29] Kaburaki J., Kuwana M., Yamamoto M., Kawai S., Ikeda Y., Clinical significance of anti-annexin V antibodies in patients with systemic lupus erythematosus, Am. J. Hematol., 1997, 54, 209–213 http://dx.doi.org/10.1002/(SICI)1096-8652(199703)54:3<209::AID-AJH6>3.0.CO;2-#[Crossref]
• [30] Satoh A., Suzuki K., Takayama E., Kojima K., Hidaka T., Kawakami M., et al., Detection of antiannexin IV and anti-annexin V antibodies in patients with antiphospholipid syndrome and systemic lupus erythematosus, J. Rheumatol., 1999, 26, 1715–1720
• [31] Lakos G., Kiss E., Regeczy N., Tarjan P., Soltesz P., Zeher M. et al., Antiprothrombin and anti annexin V antibodies imply risk of thrombosis in patients with systemic autoimmune diseases, J. Rheumatol., 2000, 27, 924–929
• [32] Nojima J, Kuratsune H, Suehisa E, Futsukaichi Y, Yamanishi H, Machii T., et al., Association between the prevalence of antibodies to β2-glycoprotein I, prothrombin, protein C, protein S, and annexin V in patients with systemic lupus erythematosus and thrombotic and thrombocytopenic complications, Clin. Chem. 2001, 47,6, 1008–1015
• [33] de Laat B., Derksen R.H., Mackie I.J., Roest M., Schoormans S., Woodhams B.J., et al., Annexin A5 polymorphism (−1C→T) and the presence of anti-annexin A5 antibodies in the antiphospholipid syndrome, Ann. Rheum. Dis., 2006, 65,11, 1468–1472 http://dx.doi.org/10.1136/ard.2005.045237[Crossref]
• [34] Roldán V., Marín F., Pineda J., Marco P., Corral J., Climent V., et al., Annexin V levels in survivors of early myocardial infarction, Rev. Esp. Cardiol., 2002, 55,12, 1230–1234
• [35] Gaspersic N., Rot U., Cucnik S., Kveder T., Bozic B., Rozman B., Anti-annexin V antibodies in patients with cerebrovascular disease, Ann. Rheum. Dis., 2003, 62, 188–189 http://dx.doi.org/10.1136/ard.62.2.188[Crossref]
• [36] Sigiura K., Muro Y., Anti-annexin V antibodies and digital ischemia in patients with scleroderma, J. Rheumatol., 1999, 26, 2168–2172
• [37] Dubois T, Bisagni-Faure A, Coste J, Mavoungou E, Menkes CJ, Russo-Marie F., et al., High levels of antibodies to annexin V and VI in patients with rheumatoid arthritis, J. Rheumatol., 1995, 22, 1230–1234
• [38] Tripathy N.K., Sinha N., Nityanand S., Anti-annexin V antibodies in Takayasu’s arteritis: prevalence and relationship with disease activity, Clin. Exp. Immunol., 2003, 134, 360–364 http://dx.doi.org/10.1046/j.1365-2249.2003.02282.x[Crossref]
• [39] Bastian B.C., Nuss B., Römisch J., Kraus M., Bröcker E.B., Autoantibodies to annexins: a diagnostic marker for cutaneous disorders?, J. Dermatol. Sci., 1994, 8, 194–202 http://dx.doi.org/10.1016/0923-1811(94)90054-X[Crossref]
• [40] Lieby P., Poindron V., Roussi S., Klein C., Knapp A.-M., Garaud J.-C., et al., Pathogenic antiphospholipid antibody: an antigen-selected needle in a haystack, Blood, 104, 2004, 6, 1711–1715 http://dx.doi.org/10.1182/blood-2004-02-0462[Crossref]
• [41] Galli M., Barbui T., Prevalence of different antiphospholipid antibodies in systemic lupus erythematosus and their relationship with antiphospholipid syndrome, Clin. Chem., 47, 2001, 6, 985–987

Identifiers

DOI

10.2478/s11536-009-0132-4